Clinical trial · Observational
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer-A Retrospective Study
NCT05023720CI-TRIAL-00057481unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer- A Retrospective, Observational Study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nonintervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Regorafenib group
- description
- Patients were given only regorafenib orally
- interventionNames
- Other: nonintervention
- label
- Joint group
- description
- The patient was treated with regorafenib orally and in combination with other medications
- interventionNames
- Other: nonintervention
Primary outcomes (3)
- measure
- The difference in overall survival between the two groups calculated by Kaplan-Meier
- timeFrame
- 2021.7-2022.12
- description
- Survival differences between the monotherapy and combination groups
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
1. Inclusion Criteria: 1. Must be a pathologically proven colorectal adenocarcinoma 2. Must have been treated with regorafenib 3. Regorafenib must be used after two lines of standard antitumor therapy 2. Exclusion Criteria: 1. Application is less than one course of treatment with regorafenib 2. First - or second-line treatment with regorafenib 3. Patients with multiple primary cancers
References
Publications (0)
Data not yet available
No reference posted for this study.